Hans-Peter Gerber insider trades: Sutro Biopharma (STRO) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Hans-Peter reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | STRO | ↑ Buy | 17,000 | $0.80 | $14K | Direct | Oct 16, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Hans-Peter Gerber's insider trades
Hans-Peter Gerber is Chief Scientific Officer at Sutro Biopharma (STRO). Since Oct 15, 2025, Hans-Peter has reported 1 open-market purchase worth $14K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (5 filings), shares withheld for taxes (5 filings), grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STRO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.